Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker KTTA
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | James Silverman | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Opaleye, L.P. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Nov 6, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Opaleye Management Inc. | 0 | 0.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Vivo Opportunity Cayman, LLC | 937,567 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Vivo Opportunity Cayman Fund, L.P. | 937,567 | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Vivo Opportunity, LLC | 9.29M | 10.0% | SCHEDULE 13G/A ↗ |
| Aug 14, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Vivo Opportunity Fund Holdings, L.P. | 9.29M | 10.0% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | James Silverman | 2.05M | 6.1% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Opaleye, L.P. | 2.05M | 6.1% | SCHEDULE 13G/A ↗ |
| Jul 31, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Opaleye Management Inc. | 2.05M | 6.1% | SCHEDULE 13G/A ↗ |
| Jul 1, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Matthew D. Perry | 3.84M | 11.5% | SCHEDULE 13G/A ↗ |
| Jul 1, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Coastlands Capital LLC | 3.84M | 11.5% | SCHEDULE 13G/A ↗ |
| Jul 1, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Coastlands Capital GP LLC | 3.84M | 11.5% | SCHEDULE 13G/A ↗ |
| Jul 1, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Coastlands Capital Partners LP | 3.84M | 11.5% | SCHEDULE 13G/A ↗ |
| Jul 1, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Coastlands Capital LP | 3.84M | 11.5% | SCHEDULE 13G/A ↗ |
| Jun 23, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Jon M. Plexico | 1.95M | 5.8% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Stonepine GP, LLC | 1.95M | 5.8% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Stonepine Capital, L.P. | 1.95M | 5.8% | SCHEDULE 13G ↗ |
| Jun 23, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Stonepine Capital Management, LLC | 1.95M | 5.8% | SCHEDULE 13G ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Columbia Management Investment Advisers, LLC | 1.35M | 5.4% | SCHEDULE 13G/A ↗ |
| May 15, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Ameriprise Financial, Inc. | 1.35M | 5.4% | SCHEDULE 13G/A ↗ |
| Apr 22, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Jacob Ma-Weaver | 1.84M | 7.4% | SCHEDULE 13G ↗ |
| Apr 22, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Cable Car Capital, LP | 1.84M | 7.4% | SCHEDULE 13G ↗ |
| Apr 22, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Funicular Funds, LP | 1.84M | 7.4% | SCHEDULE 13G ↗ |
| Apr 8, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | James Silverman | 2.49M | 10.0% | SCHEDULE 13G ↗ |
| Apr 8, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Opaleye, L.P. | 2.49M | 10.0% | SCHEDULE 13G ↗ |
| Apr 8, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Opaleye Management Inc. | 2.49M | 10.0% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Matthew D. Perry | 2.39M | 10.0% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Coastlands Capital LLC | 2.39M | 10.0% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Coastlands Capital GP LLC | 2.39M | 10.0% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Coastlands Capital Partners LP | 2.39M | 10.0% | SCHEDULE 13G ↗ |
| Feb 27, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Coastlands Capital LP | 2.39M | 10.0% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | William Blank | 2.33M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Matthew Sesterhenn | 2.33M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Squadron Capital Management LLC | 2.33M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Squadron Master Fund LP | 2.33M | 9.9% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | Heights Capital Management, Inc. | 899,994 | 3.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | KTTA Pasithea Therapeutics Corp. | CVI Investments, Inc. | 899,994 | 3.8% | SCHEDULE 13G/A ↗ |
| Feb 17, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Columbia Management Investment Advisers, LLC | 1.93M | 8.4% | SCHEDULE 13G ↗ |
| Feb 17, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Ameriprise Financial, Inc. | 1.93M | 8.4% | SCHEDULE 13G ↗ |
| Feb 12, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Phillip Gross | 2.33M | 10.0% | SCHEDULE 13G ↗ |
| Feb 12, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Robert Atchinson | 2.33M | 10.0% | SCHEDULE 13G ↗ |
| Feb 12, 2026 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Adage Capital Management, L.P. | 2.33M | 10.0% | SCHEDULE 13G ↗ |
| Dec 8, 2025 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Janus Henderson Group PLC | 10.23M | 10.0% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | William Blank | 2.25M | 9.9% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Matthew Sesterhenn | 2.25M | 9.9% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Squadron Capital Management LLC | 2.25M | 9.9% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Squadron Master Fund LP | 1.65M | 7.3% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Vivo Opportunity Cayman, LLC | 1.77M | 10.0% | SCHEDULE 13G ↗ |
| Dec 5, 2025 | SCHEDULE 13G | KTTA Pasithea Therapeutics Corp. | Vivo Opportunity Cayman Fund, L.P. | 1.77M | 10.0% | SCHEDULE 13G ↗ |
The newest 50 items, most recent first. Every row links to its original filing. Updated Nov 15, 2026, 7:42 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances